The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...

Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...